Search Result

Results for "

Prostaglandin Blocker

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PGE synthase (16) Prostaglandin Receptor (23) 15-PGDH (1) Amino acid Transporter (1) Apoptosis (2) Bacterial (5) Bcr-Abl (1) Biochemical Assay Reagents (1) Calcium Channel (4) Caspase (2) Collagen (1) COX (18) Cytochrome P450 (6) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (1) Endogenous Metabolite (1) ERK (1) Ferroptosis (1) FLAP (1) Fungal (5) Glutathione Peroxidase (1) GnRH Receptor (1) GSK-3 (1) HCV (1) HCV Protease (1) Interleukin Related (2) Isotope-Labeled Compounds (2) Lipoxygenase (6) MDM-2/p53 (1) NF-κB (2) NOD-like Receptor (NLR) (2) Orthopoxvirus (1) P2X Receptor (2) Potassium Channel (1) RANKL/RANK (2) Reactive Oxygen Species (ROS) (2) Reference Standards (8) SOD (2) STAT (2) UGT (1) Xanthine Oxidase (1) β-catenin (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (6) Endocrinology (5) Infection (9) Inflammation/Immunology (29) Metabolic Disease (9) Neurological Disease (11)

By Targets:

PGE synthase (16)

Prostaglandin Receptor (23)

15-PGDH (1)

Amino acid Transporter (1)

Apoptosis (2)

Bacterial (5)

Bcr-Abl (1)

Biochemical Assay Reagents (1)

Calcium Channel (4)

Caspase (2)

Collagen (1)

COX (18)

Cytochrome P450 (6)

DNA/RNA Synthesis (1)

Drug Derivative (1)

Drug Intermediate (1)

Drug Metabolite (1)

Endogenous Metabolite (1)

ERK (1)

Ferroptosis (1)

FLAP (1)

Fungal (5)

Glutathione Peroxidase (1)

GnRH Receptor (1)

GSK-3 (1)

HCV (1)

HCV Protease (1)

Interleukin Related (2)

Isotope-Labeled Compounds (2)

Lipoxygenase (6)

MDM-2/p53 (1)

NF-κB (2)

NOD-like Receptor (NLR) (2)

Orthopoxvirus (1)

P2X Receptor (2)

Potassium Channel (1)

RANKL/RANK (2)

Reactive Oxygen Species (ROS) (2)

Reference Standards (8)

SOD (2)

STAT (2)

UGT (1)

Xanthine Oxidase (1)

β-catenin (1)

By Research Areas:

Cancer (9)

Cardiovascular Disease (6)

Endocrinology (5)

Infection (9)

Inflammation/Immunology (29)

Metabolic Disease (9)

Neurological Disease (11)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Targets Recommended: Prostaglandin Receptor PGE synthase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124108

Eicosatetraynoic acid ETYA	COX Lipoxygenase Orthopoxvirus Potassium Channel DNA/RNA Synthesis Drug Derivative	Infection Neurological Disease Inflammation/Immunology Cancer
Eicosatetraynoic acid (ETYA) is a non-metabolizable analog of Arachidonic acid (HY-109590) and also an inhibitor of the lipoxygenase (LOX)/cyclooxygenase (COX) pathway (ID₅₀= 8 μM and 4 μM). Eicosatetraynoic acid acts as a suicide substrate to inhibit the production of inflammatory mediators such as leukotrienes and prostaglandins. Eicosatetraynoic acid acts directly on cell membranes and membrane proteins to exert a wide range of effects, including blocking potassium channels, increasing cell membrane fluidity, elevating intracellular calcium levels, inhibiting DNA synthesis in tumor cells, inducing differentiation of certain cells, and specifically inhibiting the assembly and replication of orthopoxviruses. Eicosatetraynoic acid alleviates acute lung injury induced by chemicals such as phosgene .

HY-B0336

Pranoprofen 2 Publications Verification	COX Apoptosis PGE synthase	Inflammation/Immunology Cancer
Pranoprofen is a non-steroidal anti-inflammatory agent (NSAID) for the research of keratitis or other ophthalmology diseases. Pranoprofen inhibit COX-1 and COX-2 enzymes, thus blocking arachidonic acid converted to eicosanoids and reducing prostaglandins synthesis .

HY-13568

Benoxaprofen LRCL 3794	Cytochrome P450 COX Lipoxygenase PGE synthase	Inflammation/Immunology
Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .

HY-N12586

Pheophytin a	ERK Reactive Oxygen Species (ROS) COX PGE synthase STAT HCV HCV Protease	Infection Neurological Disease Cancer
Pheophytin a is a multi-target inhibitor, anticancer agent, antioxidant and antiviral agent. Pheophytin a directly binds to and inhibits HCV-NS3/4A protease (IC₅₀=0.89 μM) to block viral replication. Pheophytin a also scavenges free radicals, reduces ferric ions, and exhibits cytotoxic activity against breast cancer cells. Pheophytin a effectively inhibits LPS-induced production of nitric oxide, prostaglandin E2, NOS2 and COX-2, as well as various pro-inflammatory cytokines, by downregulating the transcription levels of inflammatory mediators and blocking the ERK1/2 and STAT-1 pathways. In a low nerve growth factor environment, Pheophytin a also enhances ERK1/2 phosphorylation and synergistically promotes neurite outgrowth through MAPK pathway. Pheophytin a can be used to investigate the pathogenic mechanisms of diseases including chronic hepatitis C, sepsis, breast cancer and Alzheimer's disease .

HY-B0885

Econazole 5 Publications Verification (±)-Econazol	Fungal Bacterial Calcium Channel Cytochrome P450	Infection Metabolic Disease
Econazole ((±)-Econazol) is an orally active imidazole antifungal agent, as well as a cytochrome P-450 inhibitor and a blocker of calcium and manganese ion uptake. Econazole is active against a variety of fungi and some Gram-positive bacteria, but has no significant activity against Gram-negative bacteria. Econazole can inhibit the synthesis of *prostaglandins* and can also induce liver damage .

HY-A0221

Ridogrel R 68070	Prostaglandin Receptor	Inflammation/Immunology
Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .

HY-B0890

Zomepirac sodium salt McN-2783-21-98	PGE synthase	Neurological Disease Inflammation/Immunology
Zomepirac sodium salt (McN-2783-21-98) is an orally active prostaglandin synthetase inhibitor. Zomepirac sodium salt blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac sodium salt can be used for the research of postoperative pain and osteoarthritis .

HY-W008393

(-)-Corey lactone diol	Drug Intermediate	Cardiovascular Disease Inflammation/Immunology
(-)-Corey lactone diol is the reduced form of Corey aldehyde. (-)-Corey lactone diol can be used as a drug intermediate for the synthesis of Beraprost (HY-13569A) .

HY-150270A

NP-1815-PX sodium	P2X Receptor Prostaglandin Receptor NOD-like Receptor (NLR) Caspase Interleukin Related	Inflammation/Immunology
NP-1815-PX sodium is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC₅₀ of 0.26 μM against human P2X4 receptors. NP-1815-PX sodium specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX sodium selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX sodium not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX sodium exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX sodium is used in studies related to asthma and inflammatory bowel disease (colitis) .

HY-139589

Zaloglanstat ISC-27864; GRC-27864	PGE synthase COX Collagen	Neurological Disease Inflammation/Immunology
Zaloglanstat (ISC-27864; GRC-27864) is a selective, orally active microsomal mPGES-1 inhibitor. Zaloglanstat has an IC₅₀ of 5 nM for human mPGES-1 without significant inhibitory effect on COX-1/2 (IC₅₀ >10 μM). Zaloglanstat blocks the conversion of arachidonic acid metabolite prostaglandin PGH₂ to prostaglandin PGE₂, thereby inhibiting inflammation-related PGE₂ overproduction and reducing inflammatory responses and pain. Zaloglanstat inhibits IL-1β-induced PGE₂ release in A549 cells and human synovial fibroblasts in vitro. Zaloglanstat inhibits PGE2 release in pig and dog whole blood with IC₅₀s ??of 161 nM and 154 nM, respectively. Zaloglanstat can be used in the study of asthma, osteoarthritis, and neurodegenerative diseases .

HY-13219

Tepoxalin	COX Lipoxygenase Reactive Oxygen Species (ROS) NF-κB	Neurological Disease Inflammation/Immunology
Tepoxalin is an orally active dual inhibitor of Cyclooxygenase/Lipoxygenase, with IC₅₀ values of 4.6 μM (sheep cyclooxygenase), 2.85 μM (rat cyclooxygenase), 0.15 μM (rat 5-lipoxygenase), and 3.0 μM (h12-lipoxygenase), respectively. Tepoxalin inhibits ROS production and NF-κB activation. Tepoxalin suppresses the production of thromboxane B₂, leukotriene B₄, prostaglandins and cytokines, and blocks platelet aggregation. Tepoxalin exhibits potent anti-inflammatory activity in rats with adjuvant-induced arthritis. Tepoxalin possesses analgesic activity. Tepoxalin shows no ulcerogenic activity within the anti-inflammatory dose range. Tepoxalin can be used in studies related to adjuvant-induced arthritis, skin inflammation and Alzheimer's disease .

HY-109532

Ganirelix acetate Ganirest	GnRH Receptor	Metabolic Disease
Ganirelix acetate (Ganirest) is a competitive and selective gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix acetate blocks endogenous GnRH-induced release of luteinizing hormone (LH) and follicle-stimulating hormone. Ganirelix acetate antagonizes Prostaglandin E2 (HY-101952)-induced detrusor overactivity and enhances Carbachol (HY-B1208)-induced detrusor contraction. Ganirelix acetate is applicable to research related to female infertility and detrusor overactivity .

HY-139578

Ocarocoxib	COX	Inflammation/Immunology
Ocarocoxib is a potent cyclooxygenase-2 (COX-2) inhibitor (IC₅₀: 1.4 μM). Ocarocoxib inhibits COX to block the production of prostaglandins, thus exerting an anti-inflammatory effect. Ocarocoxib has potential in the study of inflammation and related diseases .

HY-162387

UK4b	PGE synthase	Cardiovascular Disease Inflammation/Immunology Cancer
UK4b is a highly selective microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor. UK4b possesses anti-inflammatory and analgesic effects. UK4b can block the growth of abdominal aortic aneurysms in mice .

HY-177440

T26A	Prostaglandin Receptor COX PGE synthase	Metabolic Disease
T26A is a highly selective prostaglandin transporter (PGT) inhibitor.T26A does not interact with the PGT homolog OATPc, blocks PGT-mediated PGE₂ influx, and blocks PGE₂ metabolism.T26A retains PGE₂ in the extracellular compartment and reduces intracellular PGE₂ metabolites.T26A elevates circulating endogenous PGE₂ levels, reduces circulating endogenous PGE₂ metabolite levels, and slows metabolism of exogenously injected PGE₂ in Rattus norvegicus via intravenous injection.T26A does not affect PGE₂ synthesis.T26A can be used for the research of PGT function in adult animals .

HY-138665

HHS-0701	Prostaglandin Receptor	Endocrinology
HHS-0701, a sulfur-triazole exchange (SuTEx) ligand, is a potent tyrosine-reactive prostaglandin reductase 2 (PTGR2) inhibitor. HHS-0701 blocks PTGR2 metabolism of the lipid substrate 15-Keto-PGE2 .

HY-102065

SC-19220	Prostaglandin Receptor RANKL/RANK	Metabolic Disease
SC-19220 is a prostaglandin E₂ receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption .

HY-130046

16-Epiestriol 16-epi-Estriol; 16β,17β-Estriol	UGT Bacterial	Infection Inflammation/Immunology
16-Epiestriol (16-epi-Estriol; 16β,17β-Estriol) is a natural stereoisomer of estriol and an anti-inflammatory agent that targets UGT. The Ki values of 16-Epiestriol against human UGT1A10 and UGT2B7 are 98.1 μM and 162 μM, respectively. As a glucuronidation substrate, 16-Epiestriol can be modified at the 3-OH, 16-OH and 17-OH sites by various UGT enzymes; in liver microsomes, the modification mainly occurs at the 16-OH and 17-OH sites, while reactions take place at all three sites in intestinal microsomes. 16-Epiestriol acts on the phase II inflammatory process by blocking edema mediated by prostaglandins and leukocyte infiltration. It lacks glycogenic activity or any effect on blood glucose levels, and serves as an important candidate molecule in the research of inflammatory diseases .

HY-179041

SZ0232	PGE synthase Prostaglandin Receptor MDM-2/p53 Amino acid Transporter Glutathione Peroxidase Ferroptosis	Metabolic Disease Endocrinology
SZ0232 is a selective mPGES-2 inhibitor. SZ0232 binds to the active site of mPGES-2 via hydrogen bonds and π-π stacking, reduces the production of prostaglandin E₂ (PGE₂) and blocks the PGE₂-EP3 pathway. SZ0232 regulates Ferroptosis by activating the heme-dependent p53/SLC7A11/GPX4 axis, inhibits lipid peroxidation, and protects renal tubules. SZ0232 enhances glucose-stimulated insulin secretion, inhibits β-cell senescence, and improves glucose homeostasis. SZ0232 reduces renal lipid accumulation, alleviates fibrosis, and ameliorates renal dysfunction in diabetic mice. SZ0232 inhibits renal cyst growth in polycystic kidney disease models. SZ0232 exhibits an insulinotropic effect that strengthens with the increase of animal age. SZ0232 can be used in studies related to type 2 diabetes, acute kidney injury, diabetic kidney disease, and autosomal dominant polycystic kidney disease .

HY-169430

AGU654	PGE synthase
AGU654 (Compound 44) is a selective mPGES-1 inhibitor with an IC₅₀ of 2.9 nM against mPGES-1. AGU654 inhibits mPGES-1 to block the pathway converting arachidonic acid into prostaglandin E2 (PGE2) by COX-1/2, thereby alleviating inflammatory responses, pain, and fever. In activated human monocyte-derived macrophages and human whole blood models, AGU654 selectively suppresses bacterial exotoxin-induced PGE2 production while preserving the production of other prostaglandins. In guinea pig models, AGU654 significantly alleviates fever, inflammation, and inflammatory pain, exhibiting excellent anti-inflammatory, analgesic, and antipyretic effects. AGU654 holds promise as a strategy for studying inflammatory diseases and pain .

HY-150270

NP-1815-PX	Prostaglandin Receptor P2X Receptor NOD-like Receptor (NLR) Caspase Interleukin Related	Neurological Disease Inflammation/Immunology
NP-1815-PX is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC₅₀ of 0.26 μM against human P2X4 receptors. NP-1815-PX specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX is used in studies related to asthma and inflammatory bowel disease (colitis) .

HY-151173

XO/COX/LOX-IN-1	Xanthine Oxidase Lipoxygenase COX	Metabolic Disease Inflammation/Immunology
XO/COX/LOX-IN-1 is a XO/COX/LOX inhibitor with an IC₅₀ of 3.2 μM against rat XO, 10.83 μM against 5-LOX, 12.67 μM against COX-1, and 8.31 μM against COX-2. XO/COX/LOX-IN-1 binds to the active sites of XO, 5-LOX, COX-1 and COX-2, thereby blocking enzyme activities associated with uric acid, leukotriene, prostaglandin synthesis and inflammatory pathways. XO/COX/LOX-IN-1 can be used in the research of hyperuricemia and inflammation .

HY-P10457

15-Hydroxy prostaglandin dehydrogenase blocking peptide 15-PGDH (92-105)	15-PGDH	Others
5-Hydroxy prostaglandin dehydrogenase blocking peptide (15-PGDH (92-105)) is a blocking peptide that corresponds to the amino acids (AGVNNEKNWEKTLQ) located at positions 92-105 of the 15-hydroxy prostaglandin dehydrogenase (15-PGDH) sequence. 5-Hydroxy prostaglandin dehydrogenase blocking peptide can block the formation of protein-antibody complexes during immunohistochemical analysis of 15-PGDH .

HY-W268542

4-Acetylaminoantipyrine	COX SOD PGE synthase	Inflammation/Immunology Cancer
4-Acetylaminoantipyrine (4-AA) is a derivative of antipyrine (HY-B0171). 4-Acetylaminoantipyrine acts as a PGE2-dependent blocker and inhibitor of cyclooxygenase (COX) . 4-Acetylaminoantipyrine can inhibit Cu/ZnSOD . 4-Acetylaminoantipyrine can spontaneously bind with bovine serum albumin (BSA) and alter its conformation .

HY-178792

TGI-15	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
TGI-15 is a highly selective prostaglandin F receptor antagonist. TGI-15 inhibits downstream signaling pathways by blocking the binding of PGF2 α to FP receptors. TGI-15 can be used for research on fibrotic and inflammatory conditions .

HY-10419A

AH23848 hemicalcium salt 1 Publications Verification	Prostaglandin Receptor	Cardiovascular Disease
AH23848 hemicalcium salt is an orally active, selective competitive blocker of the thromboxane A₂ receptor, with an IC₅₀ value of 50 nM. AH23848 hemicalcium salt shows no activity against other prostaglandin, serotonin (5-HT) or adenosine diphosphate (ADP) receptors. AH23848 hemicalcium salt can be used in the research of occlusive vascular diseases .

HY-105866

Wy 27569	Calcium Channel Prostaglandin Receptor	Cardiovascular Disease
Wy 27569 is an orally active vascular selective calcium channel blocker that can effectively lower blood pressure. Wy 27569 is a thromboxane synthase inhibitor that can reshape prostaglandin balance, reduce pro thrombotic TXA2, and increase anti thrombotic PGI2. Wy 27569 can be used for research on cardiovascular diseases such as hypertension and angina .

HY-B0885R

Econazole (Standard) (±)-Econazol (Standard)	Reference Standards Fungal Bacterial Calcium Channel Cytochrome P450	Infection Metabolic Disease
Econazole (Standard) ((±)-Econazol (Standard)) is the analytical standard of Econazole (HY-B0885). This product is intended for research and analytical applications. Econazole ((±)-Econazol) is an orally active imidazole antifungal agent, as well as a cytochrome P-450 inhibitor and a blocker of calcium and manganese ion uptake. Econazole is active against a variety of fungi and some Gram-positive bacteria, but has no significant activity against Gram-negative bacteria. Econazole can inhibit the synthesis of *prostaglandins* and can also induce liver damage .

HY-165587

BM-573	Prostaglandin Receptor	Cardiovascular Disease
BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC₅₀ of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock .

HY-114761

Prostaglandin F2α dimethyl amine	Prostaglandin Receptor	Cardiovascular Disease
Prostaglandin F2α dimethyl amine is a Prostaglandin F2α (HY-12956) derivative. Prostaglandin F2α dimethyl amine is an antagonist for Prostaglandin F receptor (FP) . Prostaglandin F2α dimethyl amine blocks the cardiovascular responses induced by orexin and Arachidonic acid (HY-109590) .

HY-W268542R

4-Acetylaminoantipyrine (Standard)	Reference Standards COX SOD PGE synthase	Inflammation/Immunology Cancer
4-Acetylaminoantipyrine (Standard) is the analytical standard of 4-Acetylaminoantipyrine. This product is intended for research and analytical applications. 4-Acetylaminoantipyrine (4-AA) is a derivative of antipyrine (HY-B0171). 4-Acetylaminoantipyrine acts as a PGE2-dependent blocker and inhibitor of cyclooxygenase (COX) . 4-Acetylaminoantipyrine can inhibit Cu/ZnSOD . 4-Acetylaminoantipyrine can spontaneously bind with bovine serum albumin (BSA) and alter its conformation .

HY-P1020

Nocistatin(human)	Prostaglandin Receptor	Neurological Disease
Nocistatin (human) blocks nociceptin-induced allodynia and hyperalgesia, and attenuates pain evoked by prostaglandin E₂ .

HY-139119

Prostaglandin F2α dimethyl amide	Prostaglandin Receptor	Others
Prostaglandin F2α dimethyl amide is an antagonist for Prostaglandin F2α (HY-12956), which blocks 50% contraction on gerbilMeriones unguiculatus colon induced by PGF2α at 3.2 μg/mL .

HY-P1020A

Nocistatin(human) TFA	Prostaglandin Receptor	Neurological Disease
Nocistatin (human) TFA blocks nociceptin-induced allodynia and hyperalgesia, and attenuates pain evoked by prostaglandin E₂ .

HY-B0890A

Zomepirac McN-2783-21-98 free acid	PGE synthase	Neurological Disease Inflammation/Immunology
Zomepirac (McN-2783-21-98 free acid) is an orally active prostaglandin synthetase inhibitor. Zomepirac blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac can be used for the research of postoperative pain and osteoarthritis .

HY-101236

ICI 192605	Prostaglandin Receptor	Endocrinology
ICI 192605 is a potent TXA2R (thromboxane A2 receptor) antagonist as cell signaling prostaglandin. ICI 192605 blocks contraction of isolated guinea pig trachea induced by U-46619 .

HY-B0890R

Zomepirac sodium salt (Standard) McN-2783-21-98 (Standard)	PGE synthase Reference Standards	Neurological Disease Inflammation/Immunology
Zomepirac sodium salt (Standard) is the analytical standard of Zomepirac sodium salt (HY-B0890). This product is intended for research and analytical applications. Zomepirac sodium salt (McN-2783-21-98) is an orally active prostaglandin synthetase inhibitor. Zomepirac sodium salt blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac sodium salt can be used for the research of postoperative pain and osteoarthritis .

HY-B0336R

Pranoprofen (Standard)	Reference Standards COX Apoptosis PGE synthase	Inflammation/Immunology Cancer
Pranoprofen (Standard) is the analytical standard of Pranoprofen. This product is intended for research and analytical applications. Pranoprofen is a non-steroidal anti-inflammatory agent (NSAID) for the research of keratitis or other ophthalmology diseases. Pranoprofen inhibit COX-1 and COX-2 enzymes, thus blocking arachidonic acid converted to eicosanoids and reducing prostaglandins synthesis .

HY-168766

O-Acetylsalicylhydroxamic acid	Prostaglandin Receptor COX	Inflammation/Immunology
O-Acetylsalicylhydroxamic acid is an acetylation inhibitor of prostaglandin H2 synthase that can suppress PGE2 synthesis in the body and block the cyclooxygenase activity of PGHS in vitro. O-Acetylsalicylhydroxamic acid requires the presence of the active site residue Ser-529 to act on human PGHS-1; the S529A mutant is resistant to the inactivation effects of this inhibitor .

HY-P0193

Nocistatin (Bovine)	Biochemical Assay Reagents	Neurological Disease Endocrinology
Nocistatin (Bovine) is a nociceptin precursor contains another biologically active peptide. Nocistatin (Bovine) blocks nociception-induced allodynia and hyperalgesia. Nocistatin (Bovine) also attenuates pain evoked by prostaglandin E2. Nocistatin (Bovine) can bind to the membrane of mouse brain and spinal cord with high affinity. Nocistatin (Bovine) can be studied in research on pain transmission .

HY-B0885S

Econazole-d6 (±)-Econazol-d₆	Isotope-Labeled Compounds Fungal Bacterial Calcium Channel Cytochrome P450	Infection Metabolic Disease
Econazole-d₆ ((±)-Econazol-d₆) is the deuterium labeled Econazole (HY-B0885). Econazole is an orally active imidazole antifungal agent, as well as a cytochrome P-450 inhibitor and a blocker of calcium and manganese ion uptake. Econazole is active against a variety of fungi and some Gram-positive bacteria, but has no significant activity against Gram-negative bacteria. Econazole can inhibit the synthesis of prostaglandins and can also induce liver damage .

HY-W778179

Benoxaprofen-13C,d3 LRCL 3794-¹³C,d₃	Isotope-Labeled Compounds COX Cytochrome P450 Lipoxygenase PGE synthase	Inflammation/Immunology
Benoxaprofen- ¹³C, d₃ is the ¹³C-labeled Benoxaprofen (HY-13568). Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .

HY-13568R

Benoxaprofen (Standard) LRCL 3794 (Standard)	Reference Standards COX Cytochrome P450 Lipoxygenase PGE synthase	Inflammation/Immunology
Benoxaprofen (Standard) is the analytical standard of Benoxaprofen. This product is intended for research and analytical applications. Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .

HY-131384

8,11,14-Eicosatriynoic acid 8,11,14-Icosatriynoic acid	COX	Others
8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization . 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-A0221R

Ridogrel (Standard) R 68070 (Standard)	Prostaglandin Receptor Reference Standards	Inflammation/Immunology
Ridogrel (Standard) is the analytical standard of Ridogrel. This product is intended for research and analytical applications. Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .

HY-183845

HTL0039732	Prostaglandin Receptor	Cancer
HTL0039732 is an orally active antagonist of the prostaglandin EP4 receptor (Prostaglandin E2 Receptor EP4). HTL0039732 reverses PGE₂-induced differentiation toward M2-like macrophages. HTL0039732 exhibits efficacy in syngeneic tumor models and acts synergistically with PD-1/PD-L1 pathway blockers. HTL0039732 can be used for the research of advanced solid tumors .

HY-W740009

4-Oxoetodolac	Drug Metabolite Prostaglandin Receptor	Inflammation/Immunology
4-Oxoetodolac, Etodolac (HY-76251) metabolite, is an orally active antiinflammatory agent. 4-Oxoetodolac blocks prostaglandin production in cultured chondrocyte cells. 4-Oxoetodolac exhibits slight antiinflammatory activity in a rat adjuvant edema model. 4-Oxoetodolac can be used for the research of inflammation .

HY-N16849

Myristinin A YM 26567-1	COX Prostaglandin Receptor Fungal	Infection Inflammation/Immunology
Myristinin A (YM 26567-1) is a trans-isomer flavan compound found in Horsfieldia amygdaline and Myristica cinnamomea. Myristinin A can selectively inhibit COX-2 activity with an IC₅₀ of 16.9 μg/mL. Myristinin A can reduce the production of prostaglandin E2 (PGE2) and inhibit phospholipase A2 (PLA2), thereby blocking the release of inflammatory mediators. Myristinin A can inhibit Candida albicans with an IC₅₀ of 8.8 μg/mL. Myristinin A can be used for the research of inflammation and infection, such as rheumatoid arthritis .

HY-102065R

SC-19220 (Standard)	Reference Standards Prostaglandin Receptor RANKL/RANK	Metabolic Disease
SC-19220 (Standard) is the analytical standard of SC-19220 (HY-102065). This product is intended for research and analytical applications. SC-19220 is a prostaglandin E₂ receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption .

HY-N16865

Myristinin B/C	COX Prostaglandin Receptor Fungal	Infection Inflammation/Immunology
Myristinin B/C is a mixture of Myristinin B and Myristinin C. Myristinin B/C is a flavan compound found in Horsfieldia amygdaline and Myristica cinnamomea. Myristinin B/C can selectively inhibit COX-2 activity with an IC₅₀ of 2.1 μg/mL. Myristinin B/C can reduce the production of prostaglandin E2 (PGE2) and inhibit phospholipase A2 (PLA2), thereby blocking the release of inflammatory mediators. Myristinin B/C can inhibit Candida albicans with an IC₅₀ of 6 μg/mL. Myristinin B/C can be used for the research of inflammation and infection, such as rheumatoid arthritis .

Cat. No.	Product Name	Type

HY-12292G

IM-12

Fluorescent Dyes

IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS and COX-2, and induces ER stress, Ca ²⁺ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABL ^T315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia .

Cat. No.	Product Name	Type

HY-131384

8,11,14-Eicosatriynoic acid

8,11,14-Icosatriynoic acid

Biochemical Assay Reagents

8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization . 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-12292G

IM-12

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P10457

15-Hydroxy prostaglandin dehydrogenase blocking peptide 15-PGDH (92-105)	15-PGDH	Others
5-Hydroxy prostaglandin dehydrogenase blocking peptide (15-PGDH (92-105)) is a blocking peptide that corresponds to the amino acids (AGVNNEKNWEKTLQ) located at positions 92-105 of the 15-hydroxy prostaglandin dehydrogenase (15-PGDH) sequence. 5-Hydroxy prostaglandin dehydrogenase blocking peptide can block the formation of protein-antibody complexes during immunohistochemical analysis of 15-PGDH .

HY-P1020

Nocistatin(human)	Prostaglandin Receptor	Neurological Disease
Nocistatin (human) blocks nociceptin-induced allodynia and hyperalgesia, and attenuates pain evoked by prostaglandin E₂ .

HY-P1020A

Nocistatin(human) TFA	Prostaglandin Receptor	Neurological Disease
Nocistatin (human) TFA blocks nociceptin-induced allodynia and hyperalgesia, and attenuates pain evoked by prostaglandin E₂ .

HY-P0193

Nocistatin (Bovine)	Biochemical Assay Reagents	Neurological Disease Endocrinology
Nocistatin (Bovine) is a nociceptin precursor contains another biologically active peptide. Nocistatin (Bovine) blocks nociception-induced allodynia and hyperalgesia. Nocistatin (Bovine) also attenuates pain evoked by prostaglandin E2. Nocistatin (Bovine) can bind to the membrane of mouse brain and spinal cord with high affinity. Nocistatin (Bovine) can be studied in research on pain transmission .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12586

Pheophytin a	Suaeda vermiculata Forssk. ex J.F.Gmel. Structural Classification Alkaloids Other Alkaloids Amaranthaceae Plants Source Classification	ERK Reactive Oxygen Species (ROS) COX PGE synthase STAT HCV HCV Protease
Pheophytin a is a multi-target inhibitor, anticancer agent, antioxidant and antiviral agent. Pheophytin a directly binds to and inhibits HCV-NS3/4A protease (IC₅₀=0.89 μM) to block viral replication. Pheophytin a also scavenges free radicals, reduces ferric ions, and exhibits cytotoxic activity against breast cancer cells. Pheophytin a effectively inhibits LPS-induced production of nitric oxide, prostaglandin E2, NOS2 and COX-2, as well as various pro-inflammatory cytokines, by downregulating the transcription levels of inflammatory mediators and blocking the ERK1/2 and STAT-1 pathways. In a low nerve growth factor environment, Pheophytin a also enhances ERK1/2 phosphorylation and synergistically promotes neurite outgrowth through MAPK pathway. Pheophytin a can be used to investigate the pathogenic mechanisms of diseases including chronic hepatitis C, sepsis, breast cancer and Alzheimer's disease .

HY-W008393

(-)-Corey lactone diol	Classification of Application Fields Other Diseases Disease Research Fields	Drug Intermediate
(-)-Corey lactone diol is the reduced form of Corey aldehyde. (-)-Corey lactone diol can be used as a drug intermediate for the synthesis of Beraprost (HY-13569A) .

HY-N16849

Myristinin A YM 26567-1	Structural Classification Horsfieldia amygdalina (Wall. ex Hook. f. & Thomson) Warb. Coumarins Myristicaceae Phenylpropanoids Plants Source Classification	COX Prostaglandin Receptor Fungal
Myristinin A (YM 26567-1) is a trans-isomer flavan compound found in Horsfieldia amygdaline and Myristica cinnamomea. Myristinin A can selectively inhibit COX-2 activity with an IC₅₀ of 16.9 μg/mL. Myristinin A can reduce the production of prostaglandin E2 (PGE2) and inhibit phospholipase A2 (PLA2), thereby blocking the release of inflammatory mediators. Myristinin A can inhibit Candida albicans with an IC₅₀ of 8.8 μg/mL. Myristinin A can be used for the research of inflammation and infection, such as rheumatoid arthritis .

HY-N16865

Myristinin B/C	Structural Classification Horsfieldia amygdalina (Wall. ex Hook. f. & Thomson) Warb. Coumarins Myristicaceae Phenylpropanoids Plants Source Classification	COX Prostaglandin Receptor Fungal
Myristinin B/C is a mixture of Myristinin B and Myristinin C. Myristinin B/C is a flavan compound found in Horsfieldia amygdaline and Myristica cinnamomea. Myristinin B/C can selectively inhibit COX-2 activity with an IC₅₀ of 2.1 μg/mL. Myristinin B/C can reduce the production of prostaglandin E2 (PGE2) and inhibit phospholipase A2 (PLA2), thereby blocking the release of inflammatory mediators. Myristinin B/C can inhibit Candida albicans with an IC₅₀ of 6 μg/mL. Myristinin B/C can be used for the research of inflammation and infection, such as rheumatoid arthritis .

Cat. No.	Product Name	Chemical Structure

HY-B0885S

Econazole-d6

Econazole-d₆ ((±)-Econazol-d₆) is the deuterium labeled Econazole (HY-B0885). Econazole is an orally active imidazole antifungal agent, as well as a cytochrome P-450 inhibitor and a blocker of calcium and manganese ion uptake. Econazole is active against a variety of fungi and some Gram-positive bacteria, but has no significant activity against Gram-negative bacteria. Econazole can inhibit the synthesis of prostaglandins and can also induce liver damage .

HY-W778179

Benoxaprofen-13C,d3

Benoxaprofen- ¹³C, d₃ is the ¹³C-labeled Benoxaprofen (HY-13568). Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .

Targets Recommended: Prostaglandin Receptor PGE synthase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12292G

IM-12	NF-κB STAT GSK-3 β-catenin Bcr-Abl	Cancer
IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS and COX-2, and induces ER stress, Ca ²⁺ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABL ^T315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Prostaglandin Blocker

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products